Regen Biopharma, Inc.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Regen Biopharma, Inc..The latest application filed is for "suppression of pathological angiogenesis by inhibition of nr2f6".

Company Profile

3.7.25

Regen Biopharma, Inc. - Medina MN US
Regen Biopharma, Inc. - La Mesa CA US
Regen Biopharma, Inc - La Mesa CA US
Regen BioPharma, Inc. - Le Mesa CA US

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.
Trademarks

Patent Activity

Patent	Date
Suppression of Pathological Angiogenesis by Inhibition of NR2F6 App 20220290158 - Ichim; Thomas ; et al.	2022-09-15
Small molecule modulators of NR2F6 activity Grant 11,241,427 - Koos , et al. February 8, 2	2022-02-08
Enhanced Dendritic Cell Immune Activation By Combined Inhibition Of Nr2f6 With Cannibidiol App 20210403866 - Ichim; Thomas ; et al.	2021-12-30
Reduction Of Post-surgery Cancer Metastasis By Combination Of Cannabidiol And Nr2f6 Inhibition App 20210353755 - Ichim; Thomas ; et al.	2021-11-18
Nr2f6 Inhibited Chimeric Antigen Receptor Cells App 20210317180 - Ichim; Thomas ; et al.	2021-10-14
Universal donor checkpoint inhibitor silenced/gene edited cord blood killer cells Grant 11,141,471 - Ichim , et al. October 12, 2	2021-10-12
Antigen specific mRNA cellular cancer vaccines Grant 11,090,332 - Koos , et al. August 17, 2	2021-08-17
Methods and means of generating IL-17 associated antitumor effector cells by inhibition of NR2F6 inhibition Grant 11,053,503 - Koos , et al. July 6, 2	2021-07-06
Stimulation Of T Regulatory Cells By Cannabidiol As A Means Of Treating Arthritis And Autoimmunity App 20210059962 - Ichim; Thomas ; et al.	2021-03-04
Small Molecule Modulators Of Nr2f6 Activity App 20190358224 - KOOS; David ; et al.	2019-11-28
Small Molecule Agonists And Antagonists Of Nr2f6 Activity App 20180346456 - Lander; Harry M. ; et al.	2018-12-06
Methods of screening compounds that can modulate NR2F6 by displacement of a reference ligand Grant 10,088,485 - Ichim October 2, 2	2018-10-02
Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans App 20180214413 - Lander; Harry M. ; et al.	2018-08-02
Methods And Means Of Generating Il-17 Associated Antitumor Effector Cells By Inhibition Of Nr2f6 Inhibition App 20170362596 - KOOS; David ; et al.	2017-12-21
Universal Donor Checkpoint Inhibitor Silenced/gene Edited Cord Blood Killer Cells App 20170304418 - Ichim; Thomas ; et al.	2017-10-26
Antigen Specific Mrna Cellular Cancer Vaccines App 20170246207 - KOOS; David ; et al.	2017-08-31
Treatment of Liver Cancer through Embolization Depot Delivery of BORIS Gene Silencing Agents App 20170166896 - Koos; David ; et al.	2017-06-15
Immune Modulation By Tlr Activation For Treatment Of Filovirus Infections Including Ebola App 20160151469 - Ichim; Thomas	2016-06-02
Stimulation Of Immunity To Tumor Specific And Endothelial Specific Proteins By In Vivo Dc Attraction And Maturation App 20160074489 - Ichim; Thomas ; et al.	2016-03-17
Methods Of Screening Compounds That Can Modulate Nr2f6 By Displacement Of A Reference Ligand App 20160025746 - Ichim; Christine Victoria	2016-01-28
Modulation of NR2F6 and methods and uses thereof Grant 9,091,696 - Ichim , et al. July 28, 2	2015-07-28
Cells, Compositions, And Treatment Methods For Stimulation Of Hematopoiesis App 20150037303 - Ichim; Thomas ; et al.	2015-02-05
Cancer Therapy By Ex Vivo Activated Autologous Immune Cells App 20140065096 - Ichim; Thomas ; et al.	2014-03-06
Acceleration Of Hematopoietic Reconstitution By Placental Endothelial And Endothelial Progenitor Cells App 20130309210 - Ichim; Thomas	2013-11-21

Company Registrations

SEC

0001589150

Regen BioPharma Inc of NEVADA

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.